AndreaBozzo/ceres-open-data-index huggingface dataset:
Program Instruction for Tribes on the June 30, 2023 of the fourth Annual Progress and Services Report (APSR) and the CFS-101s

This Program Instruction (PI) provides guidance to Indian Tribes, Indian Tribal Organizations and Indian Tribal Consortia (hereafter “tribes,” unless otherwise noted) on actions they are required to take to receive their allotments authorized under title IV-B, subparts 1 and 2, and Chafee and ETV programs for Federal Fiscal Year (FY) 2024 (subject to the availability of appropriations).

PI-23-02

Fiscal Year 2022 Allotments to Tribes/Tribal Organizations, Title IV-B, Subpart 1: Stephanie Tubbs Jones Child Welfare Services Funding
Fiscal Year 2022 Allotments to Indian Tribes/Tribal Organizations, Title IV-B, Subpart 2: Promoting Safe and Stable Families (PSSF) Grants
Fiscal Year 2022 Allotments to States and Indian Tribes/Tribal Organizations, Title IV-B: Kinship Navigator Grants
Fiscal Year 2022 Allotments to States and Indian Tribes/Tribal Organizations, John H. Chafee Foster Care Program for Successful Transition to Adulthood
Fiscal Year 2022 Allotments to States and Indian Tribes/Tribal Organizations, John H. Chafee Foster Care Program Education and Training Vouchers (CETV Grants)
Fiscal Year 2022 Allotments to Tribes/Tribal Organizations: Family First Prevention Services Act Transition Grant Funding

CFS-101 Instructions, Part I, II, and III

Introduction
Part I: Annual Budget Request for Funds under Title IV-B, Subparts 1 and 2, CAPTA State Grant, Chafee, and ETC Instructions
Part II: Annual Estimated Expenditure Summary of Child and Family Services Funds
Part III: Expenditures for Title IV-B, Subparts 1 and 2, John H. Chafee Foster Care Program for Successful Transition to Adulthood, and Education and Training Voucher (ETV) Program

CFS-101 Forms, Parts I, II and III Excel Workbook (XLSX) (Updated as of March 24, 2023)

CFS-101 Forms Part I
CFS-101 Forms Part II
CFS-101 Forms Part III

Annual Reporting of Education and Training Vouchers Awarded

Certification of Tribal Population Under Age 21 (PDF)

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400837-T1: [Translated] PRODUCTION OF ELECTRONIC COMPONENTS USING THIN FILM CIRCUIT ELEMENTS

In the manufacture of an electronic device such as an active matrix display, a vertical amorphous PIN photodiode or similar thin-film diode (D) is advantageously integrated with a polysilicon TFT (TFT1, TFT2) in a manner that permits a good degree of optimization of the respective TFT and diode properties while being compatible with the complex pixel context of the display. High temperature processes for making the active semiconductor film (10) of the TFT more crystalline than an active semiconductor film (40) of the diode and for forming the source and drain doped regions (s1,s2, d1,d2) of the TFT are carried out before depositing the active semiconductor film (40) of the diode. Thereafter, the lateral extent of the diode is defined by etching while protecting with an etch-stop film (30) an interconnection film (20) that can provide a doped bottom electrode region (41) of the diode as well as one of the doped regions (s2, g1) of the TFT.
Compound 528603: Butanamide, 3-methyl-N-propyl

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-N-propylbutanamide. Molecular Formula: C8H17NO. Molecular Weight: 143.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Program of All-Inclusive Care for the Elderly (PACE) Rates

The datasets contain reimbursement rates paid to participating Program of All-Inclusive Care for the Elderly (PACE) organizations for calendar years 2015-2022. To be eligible for the PACE program, a person must be 55 years of age or older and reside in one of the following PACE service areas: Alameda, Contra Costa, Fresno, Humboldt, Los Angeles, Orange, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Joaquin, Santa Clara, Stanislaus.
Table 11. Perceptions of Great Risk of Having Five or More Drinks of an Alcoholic Beverage Once or Twice a Week among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of perceptions of great risk of having five or more drinks of alcohol among those aged 12 or older by State and substate regions.
Provisional COVID-19 Deaths: Distribution of Deaths by Race and Hispanic Origin

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This data file contains the following indicators that can be used to illustrate potential differences in the burden of deaths due to COVID-19 according to race and ethnicity:
count of COVID-19 deaths, distribution of COVID-19 deaths, unweighted distribution of population, and weighted distribution of population.
Compound 526236: 1,2,3-Tribromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,3-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399526-T1: [Translated] PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR THE TREATMENT OF NAILS

Topically applicable agents are described, for the treatment of nail diseases and for nail care, which contain where needed, besides one or more active substance and physiologically compatible active ingredient and solution mediator, one or more compounds of the formula I <?in-line-formulae description="In-line Formulae" end="lead"?>R-O-R<SUB>1</SUB> (I) <?in-line-formulae description="In-line Formulae" end="tail"?> where R represents a straight or branched alkyl residue with 5-8 carbon atoms and R<SUB>1 </SUB>represents a formyl group or an acetyl group
Patent AT-E399663-T1: [Translated] COMPONENT, IN PARTICULAR HYBRID COMPONENT FOR A CROSS MEMBER OF A VEHICLE AND USE OF A COMPONENT

The hybrid lateral cross member (1), as an air channel for a vehicle heating and air conditioning system, has a base body (2) which is lined with a plastics material (4) at least partially. The member has at least one air flow escape (8a-8e) and an air flow guide (9) as a deflector (10) with a smooth surface (11), as a plastics body (K) with a variable thickness of 0.1-10.0 mm.
ARCHIVED: San Francisco Vaccine Access Points

Update Jan 26, 2023: This dataset is no longer being updated. Please visit https://sf.gov/get-vaccinated-against-covid-19 for information on vaccine locations. 

<strong>A. SUMMARY</strong>
Dataset contains Vaccine Access points in City and County of San Francisco as listed on https://sf.gov/vaccine-sites.  
This site list is not inclusive of all City Sites, as some mobile sites and other providers may not be included.

<strong>B. HOW THE DATASET IS CREATED</strong>
Maintained by City staff.

<strong>C. UPDATE PROCESS</strong>
Updated daily via automated process
Program Instruction (PI-20-13)

This Program Instruction (PI) provides guidance to states, territories, and insular areas (hereafter “states,” unless otherwise noted) on actions they are required to take to receive their allotments for Federal Fiscal Year (FY)1 2022 (subject to the availability of appropriations) authorized under title IV-B, subparts 1 and 2, section 106 of CAPTA, Chafee and ETV programs.

PI-20-13 (PDF)

Allotment Tables

Fiscal Year 2020 Allotment for Title IV-B, Subpart 1 Stephanie Tubbs Jones Child Welfare Services Funding
Fiscal Year 2020 Allotment for Title IV-B, Subpart 1 Disaster Relief Supplemental Funding
Fiscal Year 2020 Allotment for Title IV-B, Subpart 1 CARES Act Supplemental Funding
Fiscal Year 2020 Allotment for Title IV-B, Subpart 2 Promoting Safe and Stable Families Grants
Fiscal Year 2020 Allotment for Title IV-B, Subpart 2 Monthly Caseworker Visit Grants
Fiscal Year 2020 Allotment for Title IV-B, Subpart 2 Kinship Navigator Grants
Fiscal Year 2020 Allotment for Chafee Foster Care Program for Successful Transition to Adulthood Grants
Fiscal Year 2020 Allotment for Education and Training Vouchers Grants
Fiscal Year 2020 Allotment for CAPTA State Grants
Fiscal Year 2020 Allotment for Family First Prevention Services Act Transition Grant Funding

CFS-101 Instructions, Part I, II, and III

Introduction
Part I: Annual Budget Request for Title IV-B, Subpart 1 & 2 Funds, CAPTA, Chafee, and ETV Instructions
Part II: Annual Estimated Expenditure Summary of Child and Family Services Instructions
Part III: Expenditures for Title IV-B, Subparts 1 and 2, Chafee Foster Care Program for Successful Transition to Adulthood (Chafee) and Education and Training Voucher (ETV) Programs Instructions

CFS-101 Forms, Parts I, II and III Excel Workbook (XLSX)

CFS-101 Forms Part I
CFS-101 Forms Part II
CFS-101 Forms Part III

CB Regional Program Managers

Annual Reporting of Education and Training Vouchers Awarded

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400342-T1: [Translated] BACKWASH FILTER

An inline backwash, flushing filter assembly comprising a header assembly, a rotatable valve assembly, and a filter element assembly disposed within a filter housing assembly. In operation, the controller moves the turn knob of the rotatable valve assembly a one-quarter turn which results in the reversal of fluid flow through the assembly to periodically back flush the filter utilizing fluid from the system inlet. Debris removed from the filter element during the backwash process are immediately discharged from the system through a drain port. Simultaneously, the hydraulic shearing mechanism of the backwash process dislodges and drains debris which may have accumulated on the screen and at the bottom of the lower filter assembly during normal filter operations. The controller then returns the filter assembly to filtration operation by a reverse one-quarter turn of the turn knob of the rotatable valve assembly.
2014 CMHS Uniform Reporting System (URS) Table for Maine

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Maine. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
NNDSS - TABLE 1GG. Smallpox to Streptococcal toxic shock syndrome

NNDSS - TABLE 1GG. Smallpox to Streptococcal toxic shock syndrome – 2020.  In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Patent AT-E401180-T1: [Translated] MOLD FOR MAKING CERAMIC TILES

The die has a top and a bottom half-die with each half-die having a bearing plate that exhibits two seating at forming cells. Two die-bearing shoes (6, 7) are partially inserted and sealedly coupled internally of the seating in a parallel direction. Each shoe delimits with a relative seating with a closed chamber (10, 11). Each closed chamber is in fluid e.g. oil communication with the other closed chamber.
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of RSV Monoclonal Antibody, and Intent for RSV Monoclonal Antibody Receipt Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV

• Infant Protection Against RSV by Maternal RSV Vaccination or Receipt of Monoclonal Antibody, and Intent for RSV Monoclonal Antibody Receipt, Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV Season (Born Since April 1, 2025), by Month of Interview

• Monthly estimates of infant protection against RSV by maternal RSV vaccination or infant receipt of RSV monoclonal antibody (nirsevimab or clesrovimab), as well as intent for RSV monoclonal antibody receipt, were calculated using data from the National Immunization Surveys (NIS) – Fall Respiratory Virus Module (NIS–FRVM) (https://www.cdc.gov/nis/about/index.html). The NIS–FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. Data were reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2025). All estimates are based upon parent-reported receipt of RSV monoclonal antibody.
Compound 527058: 2-Cyclohexen-1-one, 3,5,5-trimethyl-4-(3-oxo-1-butenylidene)

Chemical compound data from PubChem database. Molecular Formula: C13H16O2. Molecular Weight: 204.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Oral cancer treatment costs in Greece and the effect of advanced disease

Background
          The main purpose of the study was to quantify the direct costs of oral cancer treatment to the healthcare system of Greece. Another aim was to identify factors that affect costs and potential cost reduction items. More specifically, we examined the relationship between stage of disease, modality of treatment and total direct costs.
        
        
          Methods
          The medical records and clinic files of the Oral and Maxillofacial Clinic of the Athens General Hospital "Genimatas" were abstracted to investigate clinical treatment characteristics, including length of hospitalization, modes of treatment, stage of disease etc. Records of 95 patients with oral squamous cell carcinoma (OSSC), with at least six months of follow-up, were examined. The clinical data was then used to calculate actual direct costs, based on 2001 market values.
        
        
          Results
          The mean total direct costs for OSSC treatment estimated at euro 8,450 or approximately US$ 7,450. Costs depended on the stage of the disease, with significant increases in stages III and IV, as compared with stages I and II (p < 0.05). Multi-modality treatment applied mainly to patients in stages III and IV was the factor that affected the cost. Disease stage was also associated with the total duration of hospitalization (p < 0.05).
        
        
          Conclusions
          The clinical management of advanced oral cancer is strongly associated with higher costs. Although the ideal would be to prevent cancer, the combination of high-risk screening, early diagnosis and early treatment seems the most efficient way to reduce costs, and most importantly, prolong life.
Patent AT-E401408-T1: [Translated] TAPETUM SPECIFIC PROMOTORS

The present invention relates to nucleic acid sequences encoding tapetum specific promoters, for use in Artificial Male Sterility systems in plants. In particular, the promoters may be the pMAC2 promoter; the pMAC20 promoter; or promoter sequences which naturally controls the expression of a coding sequence substantially homologous to the MAC2 or MAC20 coding sequences. Also provided are regulatory elements of the promoters; plant cells and plants transformed with the promoter sequences.
Compound 528304: Pyrazine, 2-heptyl-3-methoxy

Chemical compound data from PubChem database. IUPAC Name: 2-heptyl-3-methoxypyrazine. Molecular Formula: C12H20N2O. Molecular Weight: 208.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528163: 1,3-Cyclopentadiene, 1-(1-methylethyl)

Chemical compound data from PubChem database. IUPAC Name: 1-propan-2-ylcyclopenta-1,3-diene. Molecular Formula: C8H12. Molecular Weight: 108.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526660: [(2-{3,4-Bis[(trimethylsilyl)oxy]phenyl}-3,5-bis[(trimethylsilyl)oxy]-3,4-dihydro-2H-chromen-7-yl)oxy](trimethyl)silane

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-trimethylsilyloxy-4-[3,5,7-tris(trimethylsilyloxy)-3,4-dihydro-2H-chromen-2-yl]phenoxy]silane. Molecular Formula: C30H54O6Si5. Molecular Weight: 651.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525816: N-Phenyl-N'-(3-methoxyphenyl)formamidine

Chemical compound data from PubChem database. IUPAC Name: N-(3-methoxyphenyl)-N'-phenylmethanimidamide. Molecular Formula: C14H14N2O. Molecular Weight: 226.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Site-specific mutations of FtsZ - effects on GTPase and in vitro assembly

Background
          FtsZ, the major cytoskeletal protein in bacterial cytokinesis, assembles in vitro into protofilaments, which can further associate into sheets, bundles or tubes. We have constructed 16 site-directed mutants of E. coli ftsZ, and tested them for GTP hydrolysis and assembly in vitro, and for their ability to complement the temperature sensitive ftsZ84 mutation in E. coli.
        
        
          Results
          The mutants were grouped into three classes. Benign mutants, which mapped mostly to the front and back surface of the protofilament, were able to complement ftsZ84 in vivo and showed normal assembly in vitro. GTP contact mutations had less than 10% of wild type GTPase activity. They could all assemble in vitro, and several of these mutants could complement ftsZ84. A third, and newly discovered, class of mutations mapped to the sides of the protofilaments. These lateral mutants had mostly normal GTPase and assembly in vitro, but none of them complemented ftsZ84. The non-complementing mutants showed greatly reduced expression from the pBS58 vector, suggesting possible dominant negative effects.
        
        
          Conclusions
          Several mutants with greatly reduced GTPase could still complement ftsZ84, suggesting that the high level of GTPase observed in vitro is not essential for in vivo function. All of the lateral mutants failed to complement ftsZ84, which suggests that these surfaces of the protofilaments are important for function in cell division. These lateral surfaces may mediate association of FtsZ protofilaments into pairs or small sheets, although their structure is apparently different from the sheets assembled in DEAE dextran or calcium.
Compound 527361: 18,22,26-Trimethyl-tetratriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 19,23,27-trimethylpentatriacontanenitrile. Molecular Formula: C38H75N. Molecular Weight: 546.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2011-2012 NSDUH State Prevalence Estimates Among Adults Age 18 or Older

This show the 2011-2012 NSDUH State Prevalence Estimates Among Adults Age 18 or Older. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State.
Patent AT-E399824-T1: [Translated] NON-CURVING HEAT CURING INK COMPOSITION

The present invention relates to an ink composition and a respective varnish, suitable for use in heatset printing, in particular heatset web offset printing, which is suited to avoid fluting during the printing process. The ink composition comprises at least one solvent having a boiling point of from 200°C to 240°C which is present in an amount suited to allow the ink composition to dry at a printed web temperature of from 40°C to 60°C during the printing process to avoid fluting.
Compound 526297: 1,4,9-Tribromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,4,9-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Mammography Facilities

The Mammography Facility Database is updated periodically based on information received from the four FDA-approved accreditation bodies: the American College of Radiology (ACR), and the States of Arkansas, Iowa, and Texas. Information received by FDA or Certifying State from accreditation bodies does not specify if the facility is mobile or stationary. In many instances, but not all, the accreditation body notes Mobile following the name of the facility. The certification status of facilities may change, so FDA suggests that you check the facility's current status and look for the MQSA certificate.